Market Overview:
The global emergency contraceptives market is expected to grow at a CAGR of 6.5% during the forecast period from 2018 to 2030. The market growth can be attributed to the increasing awareness about emergency contraception, rising incidence of unintended pregnancies, and technological advancements in the field of emergency contraception. The global emergency contraceptives market is segmented on the basis of type into combined estrogen and progestin pills, progestin-only (as levonorgestrel) pills, antiprogestin (as mifepristone) pills, and ulipristal acetate pills. The combined estrogen and progestin pill segment is expected to dominate the market during the forecast period owing to its high efficacy rate. On the basis of application, hospital pharmacies accounted for majority share in 2017 owing to easy availability and higher prescription rates as compared with other distribution channels such as retail pharmacies or online pharmacies. However, with increasing demand for convenient modes of purchase such as online pharmacies, this trend is likely to change in forthcoming years.
Product Definition:
Emergency contraception is a method of birth control that can be used after unprotected sex, in case your regular contraception fails (such as if a condom breaks), or if you forget to take your birth control pills. There are several types of emergency contraception available, including pills, implants, and shots.
Combined estrogen and progestin pills:
Estrogen and progestin are the female and male hormones, produced by the ovaries and testes respectively. Estrogen is responsible for breast development at puberty, while progesterone maintains the uterine lining of a woman’s uterus. Progesterone-based birth control pills were first approved by U.S.
Progestin-only (as Levonorgestrel) pills:
Progestin-only (as levonorgestrel) pills are used as emergency contraceptives to prevent pregnancy. They contain a single dose of the hormone progesterone. Progestin-only pills do not contain any estrogen, which is why they are also known as mini-pills or minipills.
Application Insights:
Based on application, the global emergency contraceptives market is segmented into hospital pharmacies, retail pharmacies, online pharmacies and others. The online pharmacy segment is expected to witness significant growth over the forecast period owing to various benefits offered such as convenience and accessibility ofEC without having to see a doctor or a pharmacist. Moreover, other advantages such as privacy and security are also expected to boost the demand for EC in this sector.
The hospital pharmacy segment held around 60% of market share in 2017 due to high usage rate of EC among women who seek healthcare services at hospitals compared with those who seek healthcare services outside these facilities. Furthermore, increasing number of hospitals offering family planning services is also anticipated fuel industry growth over the forecast period.
Regional Analysis:
Europe dominated the global emergency contraceptives market in 2017. The European Commission has approved marketing of two emergency contraceptive drugs, ulipristal acetate and ellaOne, since December 2014. In addition, the distribution of these products is also supported by the national healthcare systems in several European countries. Thus, a major factor supporting regional growth is availability of effective methods to prevent unplanned pregnancies.
Asia Pacific is expected to witness significant growth over the forecast period owing to rising awareness about various forms of contraception and increasing number of sexual partners among youth population in developing economies including India and China.
Growth Factors:
- Increasing awareness about emergency contraceptives and their benefits
- Rise in number of unplanned pregnancies due to lack of contraception use or incorrect usage
- Increased availability of emergency contraceptives through various distribution channels
- Growing popularity of over-the-counter (OTC) emergency contraceptives
- Reduction in the cost of emergency contraceptives
Scope Of The Report
Report Attributes
Report Details
Report Title
Emergency Contraceptives Market Research Report
By Type
Combined estrogen and progestin pills, Progestin-only (as Levonorgestrel) pills, Antiprogestin (as mifepristone) pills, Ulipristal acetate pills
By Application
Hospital pharmacies, Retail pharmacies, Online pharmacies, Others
By Companies
Genetics, Teva Pharmaceutical, Uniprix, Gavis Pharmaceuticals, HRA Pharma, Mankind Pharma
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
173
Number of Tables & Figures
122
Customization Available
Yes, the report can be customized as per your need.
Global Emergency Contraceptives Market Report Segments:
The global Emergency Contraceptives market is segmented on the basis of:
Types
Combined estrogen and progestin pills, Progestin-only (as Levonorgestrel) pills, Antiprogestin (as mifepristone) pills, Ulipristal acetate pills
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital pharmacies, Retail pharmacies, Online pharmacies, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Genetics
- Teva Pharmaceutical
- Uniprix
- Gavis Pharmaceuticals
- HRA Pharma
- Mankind Pharma
Highlights of The Emergency Contraceptives Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Combined estrogen and progestin pills
- Progestin-only (as Levonorgestrel) pills
- Antiprogestin (as mifepristone) pills
- Ulipristal acetate pills
- By Application:
- Hospital pharmacies
- Retail pharmacies
- Online pharmacies
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Emergency Contraceptives Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Emergency contraceptives are birth control methods that can be used to prevent pregnancy after unprotected sex. They work by preventing ovulation (the release of an egg from the ovary) or by stopping a fertilized egg from attaching to the uterus.
Some of the key players operating in the emergency contraceptives market are Genetics, Teva Pharmaceutical, Uniprix, Gavis Pharmaceuticals, HRA Pharma, Mankind Pharma.
The emergency contraceptives market is expected to register a CAGR of 6.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Emergency Contraceptives Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Emergency Contraceptives Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Emergency Contraceptives Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Emergency Contraceptives Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Emergency Contraceptives Market Size & Forecast, 2020-2028
4.5.1 Emergency Contraceptives Market Size and Y-o-Y Growth
4.5.2 Emergency Contraceptives Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Combined estrogen and progestin pills
5.2.2 Progestin-only (as Levonorgestrel) pills
5.2.3 Antiprogestin (as mifepristone) pills
5.2.4 Ulipristal acetate pills
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospital pharmacies
6.2.2 Retail pharmacies
6.2.3 Online pharmacies
6.2.4 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Emergency Contraceptives Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Emergency Contraceptives Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Combined estrogen and progestin pills
9.6.2 Progestin-only (as Levonorgestrel) pills
9.6.3 Antiprogestin (as mifepristone) pills
9.6.4 Ulipristal acetate pills
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospital pharmacies
9.10.2 Retail pharmacies
9.10.3 Online pharmacies
9.10.4 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Combined estrogen and progestin pills
10.6.2 Progestin-only (as Levonorgestrel) pills
10.6.3 Antiprogestin (as mifepristone) pills
10.6.4 Ulipristal acetate pills
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospital pharmacies
10.10.2 Retail pharmacies
10.10.3 Online pharmacies
10.10.4 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Combined estrogen and progestin pills
11.6.2 Progestin-only (as Levonorgestrel) pills
11.6.3 Antiprogestin (as mifepristone) pills
11.6.4 Ulipristal acetate pills
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospital pharmacies
11.10.2 Retail pharmacies
11.10.3 Online pharmacies
11.10.4 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Combined estrogen and progestin pills
12.6.2 Progestin-only (as Levonorgestrel) pills
12.6.3 Antiprogestin (as mifepristone) pills
12.6.4 Ulipristal acetate pills
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospital pharmacies
12.10.2 Retail pharmacies
12.10.3 Online pharmacies
12.10.4 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Combined estrogen and progestin pills
13.6.2 Progestin-only (as Levonorgestrel) pills
13.6.3 Antiprogestin (as mifepristone) pills
13.6.4 Ulipristal acetate pills
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospital pharmacies
13.10.2 Retail pharmacies
13.10.3 Online pharmacies
13.10.4 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Emergency Contraceptives Market: Competitive Dashboard
14.2 Global Emergency Contraceptives Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Genetics
14.3.2 Teva Pharmaceutical
14.3.3 Uniprix
14.3.4 Gavis Pharmaceuticals
14.3.5 HRA Pharma
14.3.6 Mankind Pharma
